Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 3—March 2025

CME ACTIVITY - Research

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

Ekaterina V. KurbatovaComments to Author , William C. Whitworth, Lakshmi Praveena Peddareddy, Patrick P.J. Phillips, Nigel A. Scott, Kia E. Bryant, Rodney Dawson, Sandra Wagner Cardoso, Wadzanai Samaneka, Melissa Engle, Ziyaad Waja, Erin Sizemore, Wendy Carr, Kelly E. Dooley, Radojka Savic, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, Payam Nahid, Nhung V. Nguyen, and AIDS Clinical Trials Group A5349,1 and Tuberculosis Trials Consortium Study 312
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, W.C. Whitworth, L.P. Peddareddy, N.A. Scott, K.E. Bryant, E. Sizemore, W. Carr); University of California– San Francisco Center for Tuberculosis, San Francisco, California, USA (P.P.J. Phillips, R. Savic, P. Nahid); University of Cape Town Lung Institute, Cape Town, South Africa (R. Dawson); Fundação Oswaldo Cruz Insituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil (S. Wagner Cardoso); Milton Park Clinical Research Site, Harare, Zimbabwe (W. Samaneka); Audie L. Murphy Veterans Administration Medical Center, San Antonio, Texas, USA (M. Engle); Wits Health Consortium Perinatal HIV Research Unit, Johannesburg, South Africa (Z. Waja); Vanderbilt University Medical Center, Nashville, Tennessee, USA (K.E. Dooley); University of Nebraska Medical Center, Omaha, Nebraska, USA (S. Swindells); Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (R.E. Chaisson); Medical University of South Carolina, Charleston, South Carolina, USA (S.E. Dorman); Vietnam National Tuberculosis Program/University of California–San Francisco Research Collaboration Unit, Hanoi, Vietnam (N.V. Nguyen)

Main Article

Table 3

AUC0–24h and Cmax in participants with and without diabetes, by tuberculosis drug, in a study assessing efficacy and safety of 4-month rifapentine-based tuberculosis treatments in persons with diabetes at sites in 12 countries,* January 2016–October 2018†

Value Diabetes status No. participants Mean SD p value‡
AUC0–24h, μg × h/mL
Rifapentine No 1,565 572.44 183.8 0.25
Yes 122 553.98 169.1
Moxifloxacin No 783 25.51 7.0 0.0001
Yes 66 22.34 6.0
Rifampin No 770 53.32 37.5 0.94
Yes 59 53.69 35.2
Isoniazid No 2,335 16.52 12.1 0.51
Yes 181 15.80 14.5
Ethambutol No 1,552 15.93 3.2 0.0002
Yes 115 14.89 2.8
Pyrazinamide No 2,335 346.14 91.5 0.48
Yes
 181
 340.77
 99.2
Cmax, μg/mL
Rifapentine No 1,565 33.10 8.7 0.17
Yes 122 31.97 8.7
Moxifloxacin No 783 2.67 0.7 0.23
Yes 66 2.55 0.8
Rifampin No 770 10.20 4.8 0.60
Yes 59 10.52 4.5
Isoniazid No 2,335 2.83 0.9 0.25
Yes 181 2.75 0.9
Ethambutol No 1,552 1.82 0.6 0.43
Yes 115 1.87 0.6
Pyrazinamide No 2,335 30.34 7.2 0.008
Yes 181 32.05 8.3

*Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, United States, Vietnam, and Zimbabwe. †AUC0–24h, area under the concentration time curve from 0–24 hours; Cmax, maximal plasma concentration. ‡A t-test was used to compare pharmacokinetic parameters between participants classified as having or not having diabetes at enrollment.

Main Article

1Members of group listed at the end of this article.

2Members of group listed at the end of this article.

Page created: January 15, 2025
Page updated: February 24, 2025
Page reviewed: February 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external